<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>cardiovascular medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>cardiovascular medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression
Authors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.
Score: 1.2, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301971
BackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="cardiovascular medicine" />
<meta property="og:description" content="Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression
Authors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.
Score: 1.2, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301971
BackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-02-04T10:38:39+00:00" />
<meta property="article:modified_time" content="2024-02-04T10:38:39+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="cardiovascular medicine"/>
<meta name="twitter:description" content="Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression
Authors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.
Score: 1.2, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301971
BackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "cardiovascular medicine",
      "item": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "cardiovascular medicine",
  "name": "cardiovascular medicine",
  "description": "Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression\nAuthors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.\nScore: 1.2, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301971\nBackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control.",
  "keywords": [
    
  ],
  "articleBody": " Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression\nAuthors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.\nScore: 1.2, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301971\nBackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP lowering effect by GLP1-RAs. MethodsA comprehensive database search for placebo-controlled randomized controlled trials (RCTs) on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with mean difference (MD) in millimeters mercury (mmHg) and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic and diastolic BP. Subgroup analyses and meta-regression were done to account for covariates. ResultsCompared to placebo, GLP-1RAs modestly reduced SBP (semaglutide: MD -3.40, [95% CI -4.22 to -2.59, p\u003c0.001], liraglutide: MD -2.61, [95% CI -3.48 to -1.74, p\u003c0.001], dulaglutide: MD -1.46, [95% CI -2.20 to -0.72, p\u003c0.001] and exenatide: MD -3.36, [95% CI - 3.63 to -3.10, p\u003c0.001]). This benefit consistently increased with longer treatment duration. Established people with type 2 diabetes experienced less SBP lowering with semaglutide. DBP reduction was only significant in the exenatide group (MD -0.94, [95% CI -1.78 to -0.1], p=0.03). Among semaglutide cohorts, mean change in hemoglobin A1c and mean change in body mass index were directly associated with SBP reduction. ConclusionPatients on GLP-1RA experienced modest SBP lowering compared to placebo. Only exenatide reduced DBP. Further studies are needed to clarify the mechanisms and the clinical benefit of GLP-1RA effects in BP reduction.\nLongitudinal Association of Mid-Life Ten Year Cardiovascular Disease Risk Score with Brain Biomarkers of Alzheimer's Disease, Neurodegeneration and White Matter Hyper Intensities in Cognitively Unimpaired Older Adults: Heart SCORE Brain Study\nAuthors: Saeed, A.; Chang, Y.; Swanson, J.; Vu, M.; Mapstone, M.; Villemagne, V. L.; Snitz, B.; Royse, S. K.; Lopresti, B.; Aizenstein, H.; Wu, M.; Kip, K. E.; Reis, S. E.; Lopez, O.; Cohen, A. D.\nScore: 1.2, Published: 2024-01-28 DOI: 10.1101/2024.01.24.24301752\nIntroductionAtherosclerotic cardiovascular disease (ASCVD) risk factors in mid-life have been associated with cognitive decline and late-life dementia. However, the role of these risk factors in preclinical Alzheimers disease (AD) pathophysiology remains elusive. We investigated whether mid-life 10-year pooled cohort equations (PCE) based ASCVD risk is associated with late-life amyloid, tau, neurodegeneration [AT(N)] measures and white matter hyperintensities (WMHI). MethodsParticipants enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study between 2003-2005 (mid-life) and underwent brain MRI and PET scans in 2018-2022 (age \u003e65 years, late-life) to detect and quantify amyloid (A, PiB-PET) and tau (T, Flortaucipir (FTP) PET) deposition, cortical thickness (N) and white matter hyperintensities (WMHIs). Mid-life PCE ASCVD risk was categorized as; borderline (5%-7.4%), intermediate (7.5%-\u003c15%), or high ([\u0026ge;]15%). Association of midlife ASCVD risk HR (5% CI) was assessed using logistic and linear regressions with A, T, or N and chi square beta coefficients for WMHI in latelife. ResultsOver a [~]16y follow up, in 135 participants (mean age 73y), A and T showed no significant association with mid-life ASCVD risk. Neurodegeneration had a graded association with mid-life ASCVD risk categories (ORASCVD high vs low risk% 6.98 [2.44-19.95]; p\u003c0.05) driven by self-identified Black race and age. In a subset n=60, ASCVD risk score was also associated with WMHIs (({beta}=0.42 {+/-} 0.22; p=0.05) in a model adjusted for inflammation and education. ConclusionsIn this asymptomatic, diverse cohort, 10y ASCVD risk was predictive of late-life neurodegeneration and white matter hyperintensities but not amyloid or tau. These data suggest that ASCVD risk factors in midlife may lead to a state of vulnerability (through increased neurodegeneration and white matter hyperintensities) which may progress to cognitive decline and dementia. Further mechanistic studies are warranted to test this hypothesis. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC=\"FIGDIR/small/24301752v1_ufig1.gif\" ALT=\"Figure 1\"\u003e View larger version (22K): org.highwire.dtl.DTLVardef@19b6da0org.highwire.dtl.DTLVardef@13a328forg.highwire.dtl.DTLVardef@1cd6ed1org.highwire.dtl.DTLVardef@267b09_HPS_FORMAT_FIGEXP M_FIG C_FIG\n",
  "wordCount" : "671",
  "inLanguage": "en",
  "datePublished": "2024-02-04T10:38:39Z",
  "dateModified": "2024-02-04T10:38:39Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      cardiovascular medicine
    </h1>
    <div class="post-meta">&lt;span&gt;updated on February 4, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.29.24301971">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.29.24301971" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.29.24301971">
        <p class="paperTitle">Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.29.24301971" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.29.24301971" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: RIVERA, F. B.; Lumbang, G. N.; Gaid, D. R. M.; Cruz, L. L.; Magalong, J. V.; Bantayan, N. R.; Lara-Breitinger, K. M.; Gulati, M.; Bakris, G. L.</p>
        <p class="info">Score: 1.2, Published: 2024-01-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.29.24301971' target='https://doi.org/10.1101/2024.01.29.24301971'> 10.1101/2024.01.29.24301971</a></p>
        <p class="abstract">BackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP lowering effect by GLP1-RAs.

MethodsA comprehensive database search for placebo-controlled randomized controlled trials (RCTs) on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with mean difference (MD) in millimeters mercury (mmHg) and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic and diastolic BP. Subgroup analyses and meta-regression were done to account for covariates.

ResultsCompared to placebo, GLP-1RAs modestly reduced SBP (semaglutide: MD -3.40, [95% CI -4.22 to -2.59, p&lt;0.001], liraglutide: MD -2.61, [95% CI -3.48 to -1.74, p&lt;0.001], dulaglutide: MD -1.46, [95% CI -2.20 to -0.72, p&lt;0.001] and exenatide: MD -3.36, [95% CI - 3.63 to -3.10, p&lt;0.001]). This benefit consistently increased with longer treatment duration. Established people with type 2 diabetes experienced less SBP lowering with semaglutide. DBP reduction was only significant in the exenatide group (MD -0.94, [95% CI -1.78 to -0.1], p=0.03). Among semaglutide cohorts, mean change in hemoglobin A1c and mean change in body mass index were directly associated with SBP reduction.

ConclusionPatients on GLP-1RA experienced modest SBP lowering compared to placebo. Only exenatide reduced DBP. Further studies are needed to clarify the mechanisms and the clinical benefit of GLP-1RA effects in BP reduction.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.24.24301752">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.24.24301752" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.24.24301752">
        <p class="paperTitle">Longitudinal Association of Mid-Life Ten Year Cardiovascular Disease Risk Score with Brain Biomarkers of Alzheimer&#39;s Disease, Neurodegeneration and White Matter Hyper Intensities in Cognitively Unimpaired Older Adults: Heart SCORE Brain Study</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.24.24301752" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.24.24301752" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Saeed, A.; Chang, Y.; Swanson, J.; Vu, M.; Mapstone, M.; Villemagne, V. L.; Snitz, B.; Royse, S. K.; Lopresti, B.; Aizenstein, H.; Wu, M.; Kip, K. E.; Reis, S. E.; Lopez, O.; Cohen, A. D.</p>
        <p class="info">Score: 1.2, Published: 2024-01-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.24.24301752' target='https://doi.org/10.1101/2024.01.24.24301752'> 10.1101/2024.01.24.24301752</a></p>
        <p class="abstract">IntroductionAtherosclerotic cardiovascular disease (ASCVD) risk factors in mid-life have been associated with cognitive decline and late-life dementia. However, the role of these risk factors in preclinical Alzheimers disease (AD) pathophysiology remains elusive. We investigated whether mid-life 10-year pooled cohort equations (PCE) based ASCVD risk is associated with late-life amyloid, tau, neurodegeneration [AT(N)] measures and white matter hyperintensities (WMHI).

MethodsParticipants enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study between 2003-2005 (mid-life) and underwent brain MRI and PET scans in 2018-2022 (age &gt;65 years, late-life) to detect and quantify amyloid (A, PiB-PET) and tau (T, Flortaucipir (FTP) PET) deposition, cortical thickness (N) and white matter hyperintensities (WMHIs). Mid-life PCE ASCVD risk was categorized as; borderline (5%-7.4%), intermediate (7.5%-&lt;15%), or high ([&amp;ge;]15%). Association of midlife ASCVD risk HR (5% CI) was assessed using logistic and linear regressions with A, T, or N and chi square beta coefficients for WMHI in latelife.

ResultsOver a [~]16y follow up, in 135 participants (mean age 73y), A and T showed no significant association with mid-life ASCVD risk. Neurodegeneration had a graded association with mid-life ASCVD risk categories (ORASCVD high vs low risk% 6.98 [2.44-19.95]; p&lt;0.05) driven by self-identified Black race and age. In a subset n=60, ASCVD risk score was also associated with WMHIs (({beta}=0.42 {&#43;/-} 0.22; p=0.05) in a model adjusted for inflammation and education.

ConclusionsIn this asymptomatic, diverse cohort, 10y ASCVD risk was predictive of late-life neurodegeneration and white matter hyperintensities but not amyloid or tau. These data suggest that ASCVD risk factors in midlife may lead to a state of vulnerability (through increased neurodegeneration and white matter hyperintensities) which may progress to cognitive decline and dementia. Further mechanistic studies are warranted to test this hypothesis.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC=&#34;FIGDIR/small/24301752v1_ufig1.gif&#34; ALT=&#34;Figure 1&#34;&gt;
View larger version (22K):
org.highwire.dtl.DTLVardef@19b6da0org.highwire.dtl.DTLVardef@13a328forg.highwire.dtl.DTLVardef@1cd6ed1org.highwire.dtl.DTLVardef@267b09_HPS_FORMAT_FIGEXP  M_FIG C_FIG</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
